Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: Prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu? Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Indium Radioisotopes
  • Lutetium
  • Prostatic Neoplasms
  • Radioisotopes
  • Radiometry
  • Yttrium Radioisotopes

abstract

  • 111In- and 177Lu-labeled J591 antibodies have similar plasma and whole-body clearance kinetics. The net retention of 111In activity by lung, liver, and spleen is slightly higher compared with that with 177Lu. These results justify using 111In as a chemical and biologic surrogate for 90Y. However, the radiation dose to the liver may be overestimated by about 25% based on 111In data. In addition, the data also suggest that 177Lu may be a potential alternative for estimating the pharmacokinetics and biodistribution of 90Y-labeled radiopharmaceuticals.

publication date

  • December 9, 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 15809486

Additional Document Info

start page

  • 634

end page

  • 41

volume

  • 46

number

  • 4